Myeloproliferative neoplasm physical examination: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
Shyam Patel (talk | contribs) |
||
| Line 7: | Line 7: | ||
Common physical examination findings associated with myeloproliferative neoplasm include:<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=PMC4363847 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref><ref name="Tefferi">{{cite journal|title=Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era|author=Tefferi A|journal=Hematology Am Soc Hematol Educ Program|date=2006|pages=240-245|pmid=17124067}}</ref><ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab</ref><ref name="pmid23049404">{{cite journal| author=Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC et al.| title=Philadelphia-negative chronic myeloproliferative neoplasms. | journal=Rev Bras Hematol Hemoter | year= 2012 | volume= 34 | issue= 2 | pages= 140-9 | pmid=23049404 | doi=10.5581/1516-8484.20120034 | pmc=PMC3459391 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23049404 }} </ref> | Common physical examination findings associated with myeloproliferative neoplasm include:<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=PMC4363847 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref><ref name="Tefferi">{{cite journal|title=Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era|author=Tefferi A|journal=Hematology Am Soc Hematol Educ Program|date=2006|pages=240-245|pmid=17124067}}</ref><ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab</ref><ref name="pmid23049404">{{cite journal| author=Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC et al.| title=Philadelphia-negative chronic myeloproliferative neoplasms. | journal=Rev Bras Hematol Hemoter | year= 2012 | volume= 34 | issue= 2 | pages= 140-9 | pmid=23049404 | doi=10.5581/1516-8484.20120034 | pmc=PMC3459391 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23049404 }} </ref> | ||
===Appearance of the Patient=== | ===Appearance of the Patient=== | ||
*Patients are usually well-appearing | *Patients are usually well-appearing at an early time point in the disease and ill-appearing at a later time point in the disease. | ||
===Vital Signs=== | ===Vital Signs=== | ||
*[[Fever]] | *[[Fever]] | ||
Revision as of 21:34, 21 June 2018
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm physical examination On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm physical examination |
|
Myeloproliferative neoplasm physical examination in the news |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Patients with myeloproliferative neoplasm are usually well-appearing. Physical examination of patients with chronic myelogenous leukemia is usually remarkable for skin bruising, fever, splenomegaly, and lymphadenopathy.[1]
Physical Examination
Common physical examination findings associated with myeloproliferative neoplasm include:[1][2][3][4]
Appearance of the Patient
- Patients are usually well-appearing at an early time point in the disease and ill-appearing at a later time point in the disease.
Vital Signs
Skin
HEENT
- Decreased vision acuity
Neck
Lungs
- Vesicular breath sounds
- Wheezing
Chest
- Axillary lymphadenopathy (usually painless)
Abdomen
Genitourinary
- Inguinal lymphadenopathy (usually painless)
- Scrotal swelling
- Priapism
References
- ↑ 1.0 1.1 Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). "Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia". Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.
- ↑ Tefferi A (2006). "Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era". Hematology Am Soc Hematol Educ Program: 240–245. PMID 17124067.
- ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab
- ↑ Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC; et al. (2012). "Philadelphia-negative chronic myeloproliferative neoplasms". Rev Bras Hematol Hemoter. 34 (2): 140–9. doi:10.5581/1516-8484.20120034. PMC 3459391. PMID 23049404.